Genprex Recognizes World Cancer Day
February 04 2021 - 8:30AM
Business Wire
Joins Global Movement to Raise Awareness and
Reduce the Burden of Cancer Worldwide
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
announces today that it joins with millions of healthcare advocates
around the world in support of World Cancer Day in order to raise
awareness, elevate the public understanding of the global cancer
burden, promote greater equity and ensure that cancer control
continues to be a priority in the world health and development
agenda.
“At Genprex, our primary focus is on the patients and
communities we serve. Toward that end, we are relentless in our
pursuit to bring innovative and life-saving oncology treatments to
patients suffering with cancers for which there are limited or no
treatment options,” said Rodney Varner, Chief Executive Officer of
Genprex. “This World Cancer Day, we extend great appreciation to
our research colleagues around the world who are working to
alleviate the global cancer burden and to the patients who
graciously offer their support through participation in clinical
trials in the hope of finding new and effective treatments, not
only for themselves, but for those who come after them.”
Genprex is reprogramming the course of cancer by developing gene
therapies that have been designed and optimized to administer
cancer-fighting genes. The Company’s lead product candidate,
REQORSA™ immunogene therapy, may be administered in combination
with approved therapies, such as targeted therapies and
immunotherapies. Genprex holds an FDA Fast Track Designation for
development of REQORSA™ in combination with EGFR inhibitor,
Tagrisso® (marketed by AstraZeneca), in non-small cell lung cancer
(NSCLC) patients whose disease progressed after treatment with
Tagrisso. Genprex is advancing plans for its upcoming Acclaim-1 and
Acclaim-2 clinical trials that combine REQORSA with Tagrisso® and
with Keytruda® (marketed by Merck & Co., Inc.), respectively,
for the treatment of NSCLC, both of which are on track to be
initiated in the first-half of 2021.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused
on developing life-changing therapies for patients with cancer and
diabetes. Genprex’s technologies are designed to administer
disease-fighting genes to provide new therapies for large patient
populations with cancer and diabetes who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to develop drug candidates to further its pipeline of
gene therapies in order to provide novel treatment approaches. The
Company’s lead product candidate, REQORSA™ (quaratusugene
ozeplasmid), is being evaluated as a treatment for non-small cell
lung cancer (NSCLC). REQORSA has a multimodal mechanism of action
that has been shown to interrupt cell signaling pathways that cause
replication and proliferation of cancer cells; re-establish
pathways for apoptosis, or programmed cell death, in cancer cells;
and modulate the immune response against cancer cells. REQORSA has
also been shown to block mechanisms that create drug resistance. In
January 2020, the U.S. Food and Drug Administration granted Fast
Track Designation for REQORSA for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR
mutations whose tumors progressed after treatment with osimertinib
alone.
For more information, please visit the Company’s web site at
www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current, regarding the Company’s future growth and
financial status and regarding our commercial partnerships and
intellectual property licenses. Risks that contribute to the
uncertain nature of the forward-looking statements include the
presence and level of the effect of our product candidates, alone
and in combination with other therapies, on cancer; the timing and
success of our clinical trials and planned clinical trials of
REQORSA™ immunogene therapy drug, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including GPX-002, our gene therapy
in diabetes, advance into clinical trials; the success of our
strategic partnerships, including those relating to manufacturing
of our product candidates; the timing and success at all of
obtaining any FDA approvals of REQORSA and our other potential
product candidates including whether we receive necessary approvals
to commence clinical trials or benefit from fast track or similar
regulatory designations; costs associated with developing our
product candidates, whether we identify and succeed in acquiring
other technologies and whether patents will ever be issued under
patent applications that are the subject of our license agreements
or otherwise. These and other risks and uncertainties are described
more fully under the caption “Risk Factors” and elsewhere in our
filings and reports with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. We
undertake no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they
were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210204005156/en/
Genprex, Inc. (877) 774-GNPX (4679) Investor
Relations GNPX Investor Relations (877) 774-GNPX (4679) ext. #2
investors@genprex.com Media Contact Genprex Media Relations
Kalyn Dabbs (877) 774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024